Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure:
1
or a pharmaceutically acceptable salt thereof, e.g. 1-(3(S)-Cyclopropyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide, and 1-(3-Cyclopropyl-3-methyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide.
A novel series of neutral thrombin inhibitors has been developed using a selection process based on docking experiments and property calculations and predictions.